Rasayana Therapeutics

What Rasayana Therapeutics does

Rasayana Therapeutics is a private, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, developing oral recombinant intestinal alkaline phosphatase (IAP) biologics that target chronic inflammatory conditions at the gut mucosal interface. Its lead program, RSY-248, is a first-in-class oral biologic in an active Phase 2 trial for gut inflammation, with a parallel preclinical/IND-enabling program in metabolic inflammation; a second program, SYN-020, was licensed in from Theriva Biologics in February 2026 and is advancing to Phase 2 after completing Phase 1 with good tolerability. The underlying mechanism is multimodal — TLR modulation, purinergic signaling, tight junction restoration, and PAMP/DAMP neutralization — designed to restore gut barrier integrity and recalibrate immune activation rather than block single downstream cytokines.

The company serves patients with chronic inflammatory conditions including inflammatory bowel disease (IBD), metabolic disease, and autoimmunity — populations characterized by incomplete remission, loss of response, and escalating therapy requirements on existing single-cytokine blockers. Rasayana's commercial model is not yet active: the company is pre-revenue and intends to derive future revenue from product sales upon regulatory approval, supplemented by milestone payments and royalties from licensing arrangements. The February 2026 SYN-020 deal with Theriva Biologics is structured as a cost-bearing development license, with $300,000 paid upfront and up to $38 million in potential milestones plus tiered single-digit royalties owed to Theriva.

Rasayana is pre-commercial and operates without disclosed distribution channels, headcount, funding rounds, management team, or institutional investors. The company has publicly stated a longer-term vision of using patient-derived multiomics data combined with AI to guide precision anti-inflammatory medicine development across the gut-organ axis, including metabolic, neuroinflammatory, and age-associated diseases, but no data assets, proprietary models, or AI/ML hires are disclosed. Ownership remains founder-led and undisclosed in public materials.

Name

Rasayana Therapeutics

Legal name

Rasayana Therapeutics

Website

https://rasayanatherapeutics.com

Company type

Private

Operating status

Operating

Short description

Rasayana Therapeutics is a private, clinical-stage biopharmaceutical company developing oral recombinant intestinal alkaline phosphatase (IAP) biologics that target chronic inflammatory conditions at the gut mucosal interface, with a lead Phase 2 program (RSY-248) in gut inflammation.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals — Gut-Targeted Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

akta.pro secondary industries

Inflammatory Bowel Disease (IBD) Care (HLAKAEAD), Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

Keywords

• Oral biologic therapeutics
• Gut inflammation therapy
• Intestinal alkaline phosphatase
• Chronic inflammatory disease
• Biopharmaceutical development

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Others

Revenue model

1. Pharmaceutical licensing and development: As a clinical-stage biopharmaceutical company, Rasayana generates value through the development and potential future commercialization of novel gut-focused therapeutics. Revenue would ultimately derive from product sales upon regulatory approval, complemented by milestone payments and royalties from licensing arrangements. Currently pre-revenue, the company is investing in advancing its pipeline.

Marketing channels1 record

Core offering

Rasayana Therapeutics is a clinical-stage biopharmaceutical company developing oral recombinant intestinal alkaline phosphatase (IAP) biologics that target the gut-immune-organ axis to treat chronic inflammatory conditions. Its lead program RSY-248 (Phase 2) and licensed program SYN-020 (advancing to Phase 2) work at the gut mucosal interface to restore barrier integrity and immune homeostasis through a multimodal mechanism. Target indications include inflammatory bowel disease, metabolic disease, and autoimmunity.

Product overview

Rasayana Therapeutics is a biopharmaceutical company developing a pipeline of gut-focused medicines targeting chronic inflammatory conditions. The company's portfolio consists of two oral biologic programs based on intestinal alkaline phosphatase (IAP): RSY-248 as the lead proprietary program in Phase 2 for gut inflammation and metabolic inflammation, and SYN-020 (licensed from Theriva Biologics) also advancing toward Phase 2. Both programs represent first-in-class oral biologics designed to restore immune and barrier homeostasis at the gut mucosal interface rather than blocking downstream inflammatory signals.

Differentiator

Problem solved

Functional benefit

Products and services

• RSY-248 RSY-248 is a first-in-class oral recombinant form of intestinal alkaline phosphatase (IAP) designed to restore immune homeostasis and barrier integrity at the gut mucosal interface for patients with chronic inflammatory conditions such as IBD, metabolic disease, and autoimmunity. It acts through a multimodal mechanism including TLR modulation, purinergic signaling, tight junction restoration, and PAMP/DAMP neutralization.
• SYN-020 SYN-020 is a recombinant bovine intestinal alkaline phosphatase drug candidate targeting gastrointestinal dysfunction, licensed from Theriva Biologics for worldwide development and commercialization by Rasayana. It has demonstrated good tolerability in Phase 1 studies and is advancing to Phase 2 for multiple chronic inflammatory indications in the GI and metabolic pipeline.

Quantifiable outcome

• Phase 2 clinical trial active for RSY-248 in gut inflammation
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Theriva BiologicscoreOEM/ Whitelabel/ Licensing Partner · 1 February 2026Rasayana Therapeutics entered into an exclusive worldwide licensing agreement with Theriva Biologics to acquire SYN-020, a recombinant intestinal alkaline phosphatase drug candidate targeting gastrointestinal dysfunction. Theriva received $300,000 upfront and is eligible for up to $38 million in development, regulatory, and sales milestones plus tiered single-digit royalties. Rasayana assumes all development costs and responsibilities, advancing SYN-020 to Phase 2 while Theriva focuses on its lead pancreatic cancer program VCN-01. The deal enables Rasayana to expand its gut-focused pipeline across multiple chronic inflammatory indications.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Theriva Biologics: Theriva is the originator of SYN-020 (recombinant bovine IAP) and Rasayana's licensor. Both companies develop recombinant intestinal alkaline phosphatase for GI dysfunction, share the same molecular class, and are the only two companies publicly advancing IAP therapeutics — making Theriva the most directly comparable peer.
• Seres Therapeutics: Seres develops microbiome-based therapeutics for IBD and other inflammatory diseases, sharing Rasayana's thesis that modulating the gut mucosal interface can treat systemic inflammatory conditions. Both are clinical-stage biotechs targeting upstream gut biology rather than single downstream cytokines.
• Vedanta Biosciences: Vedanta is a clinical-stage microbiome therapeutics company focused on IBD and immune-mediated diseases. Like Rasayana, it is built on the premise that restoring gut mucosal homeostasis can resolve chronic inflammation, and it pursues defined bacterial consortia as drug products.

Broad incumbents

• Johnson & Johnson (Janssen): Janssen markets Stelara (ustekinumab) and Tremfya (guselkumab) — IL-12/23 and IL-23 inhibitors that are core IBD and immunology therapies. J&J is one of the most entrenched immunology incumbents and a key competitive comparator for any new mechanism targeting chronic inflammation.
• Pfizer: Pfizer markets etrasimod (Velsipity) for ulcerative colitis (acquired via Arena Pharmaceuticals) and has a broad gastroenterology portfolio. Pfizer represents a large-pharma incumbent actively shaping the oral IBD landscape that Rasayana's oral IAP would compete in.
• Eli Lilly: Lilly markets Omvoh (mirikizumab), an IL-23 antibody approved for ulcerative colitis, and is actively expanding its immunology and IBD pipeline. As a large immunology incumbent with a recently launched IBD biologic, it is a direct competitive analog to Rasayana's stage of clinical advancement.
• AbbVie: AbbVie markets Humira, Skyrizi, and Rinvoq — cornerstones of modern IBD therapy — and represents the entrenched anti-cytokine paradigm Rasayana seeks to differentiate against. As the dominant IBD revenue incumbent, AbbVie is the principal competitive benchmark for any new gut-inflammation entrant.
• Takeda Pharmaceutical: Takeda markets Entyvio (vedolizumab), one of the leading gut-selective biologics for IBD. Takeda represents a broad gastroenterology incumbent whose established anti-integrin franchise overlaps with Rasayana's gut-restricted therapeutic concept.
• Bristol Myers Squibb: BMS markets Zeposia (ozanimod) and the S1P modulator franchise for ulcerative colitis and Crohn's, positioning it as a broad oral/IBD competitor. Like other large incumbents, BMS targets downstream immune pathways and competes for the same gastroenterology prescribers Rasayana would need to reach.

Emerging players

• Prolacta Bioscience: Prolacta is a smaller clinical/biology-stage company developing gut- and barrier-related biologic interventions in adjacent inflammatory and neonatal populations. It represents an emerging peer in gut-barrier-restorative therapeutics with overlapping scientific rationale to Rasayana's IAP platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rasayana Therapeutics